Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Ramelteon on Insomnia Symptoms Associated With Jet Lag in Healthy Adult Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria~* Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.~* Willing to travel from Hawaii to the East Coast and have a minimum stay of 6 days at the destination in a sleep laboratory during the entire study.~* Has lived in Hawaii for at least 12 months and has not been traveling outside of Hawaii for 4 consecutive days within 30 days prior to the Outpatient Screening Visit.~* History of sleep disturbance associated with jet lag symptoms, with at least two occurrences in the last three years, as defined in the International Classification of Sleep Disorders.~* Habitual bedtime should be determined by sleep history as between 9:00 PM and 12:00 AM as determined by sleep history prior to randomization.~* Have regular bedtime (within 1 hour) for 1 week prior to travel.~* The subject has a subjective sleep latency of less than 30 minutes and a subjective total sleep time of 6.5 hours but less than 9 hours, as determined by sleep history.~* Mean subjective sleep latency of less than 30 minutes and a mean subjective total sleep time of greater than 6.5 hours but less than 9 hours in 3 of 5 nights after the outpatient screening visit, as determined by post-sleep questionnaire.~* Willingness and ability to comply with study procedures, including travel time, sleep, and waking-hour activities, light-exposure restriction, and food intake.~* Body mass index between 18 and 34, inclusive.~* Negative test result for selected substances of abuse (including alcohol) at Initial Screening, the In-Patient Actigraphy Screening Nights 1 and 2, and the Treatment Period.~* Negative test result for hepatitis B Surface antigen and hepatitis C virus antibody.~Exclusion Criteria~* Known hypersensitivity to ramelteon or related compounds, including melatonin, and melatonin related compounds.~* History of primary sleep disorders as determined by the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition Revised within the past 6 months.~* Current sleep disorder as assessed by presence of sleep apnea, period leg movement syndrome, insomnia, daytime napping of more than 20 minutes, chronic fatigue.~* Ever had a history of seizures, sleep apnea, restless leg syndrome, periodic limb movement syndrome, or chronic obstructive pulmonary disease.~* History of psychiatric disorder (including schizophrenia, bipolar disorder, mental retardation, or cognitive disorder, anxiety, or depression) within the past 12 months.~* Current, clinically significant neurological (including cognitive), hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, hematological, or metabolic disease, as determined by the investigator.~* History of alcohol abuse within the past 12 months, as defined in Diagnostic and Statistical Manual of Mental Disorders, 4th Edition Revised, or regularly consumes more than 14 alcoholic drinks per week.~* History of drug abuse within the past 12 months, as defined in Diagnostic and Statistical Manual of Mental Disorders, 4th Edition Revised.~* Positive urine drug screen or a positive urine drug screen or alcohol breathalyzer test.~* Sleep schedule changes required by employment (eg, shift worker) within 3 months prior to the administration of single blind study medication.~* Positive hepatitis panel including anti- hepatitis A virus (only IgM is exclusionary), hepatitis B surface antigen, or anti- hepatitis C virus.~* Any clinically important abnormal finding as determined by a medical history, physical examination, electrocardiogram, or clinical laboratory tests, as determined by the investigator.~* Any additional condition(s) that in the Investigator's opinion would:~  * affect sleep/wake function~ * prohibit the subject from completing the study~ * cause a situation such that it would not be in the best interest of the subject to participate in the study.~* Participated in a weight loss program or has substantially altered their exercise routine within 30 days prior to the administration of study medication.~* Smokes greater than 3 cigarettes per day or uses tobacco products during nightly awakenings.~* Has flown across greater than 3 time zones within 28 days prior to or during screening.~* Reports high caffeine consumption (greater than 600 mg daily).~* Participated in any other investigational study and/or taken any investigational drug within 30 days or 5 half-lives of the investigational drug prior to the first dose of double blind study medication, whichever is longer.~* Used any central nervous system medication within 1 week (or 5 half lives of the drug, whichever is longer) prior to the administration of study medication. These medications must not have been used to treat psychiatric disorders.~* Used prescription or over-the-counter (OTC) hypnotic medication (including melatonin) within 3 months of the screening visits.~* Is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:~  * Anxiolytics~ * Sedatives~ * Antidepressants~ * CNS active drugs (including herbal)~ * Anticonvulsants~ * Narcotic analgesics~ * Sedating H1 antihistamines~ * St. John's Wort~ * Systemic steroids~ * Kava-kava~ * Respiratory stimulants~ * Ginkgo-biloba~ * Decongestants~ * Over-the-counter and prescription stimulants~ * Antipsychotics~ * Over-the-counter and prescription diet aids~ * Muscle Relaxants Drugs affecting sleep/wake function~ * Melatonin~ * Modafinil

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Ramelteon 1 mg QD (Type: EXPERIMENTAL): None
- Ramelteon 4 mg QD (Type: EXPERIMENTAL): None
- Ramelteon 8 mg QD (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).